Is PEG (Polyethylene Glycol) a more effective laxative than Lactulose in the treatment of a child who is constipated?
Date First Published:
July 16, 2007
Last Updated:
July 16, 2007
Report by:
Nesba Naheed, Medical Student (Manchester Royal Infirmary)
Search checked by:
Rachel Jenner, Manchester Royal Infirmary
Three-Part Question:
in a [child presenting with constipation] is a [Lactulose or PEG (Polyethylene Glycol)] more [effective as maintenance treatment after successful disimpaction]?
Clinical Scenario:
A five year old child presents to the Emergency Department complaining of abdominal pains and not having passed a stool for at least two weeks. After an abdominal examination you diagnose faecal impaction. After the child has been successfully disimpacted, you are about to decide on the maintenance treatment you wonder whether there would be any difference in efficacy of the treatment if you used Movicol instead of Lactulose.
Search Strategy:
Medline 1950- May 2007 and Embase 1980 to May 2007 using OVID interface. I also searched the Cochrane database and Cinahl
Search Details:
(Exp Constipation or constipation.mp or Exp fecal impaction or fece$.mp or faec$.mp or stool$.mp ) and ( osmotic adj laxative.mp or Exp Cathartics or laxative$.mp or ((Exp lactulose or lactulose.mp) and (Exp macrogol or Exp Polyethylene Glycol or movicol.mp))) limited to humans, English language and using a paediatrics filter.
Outcome:
721 papers were found of which five were found to be relevant to the question. The rest of the papers were discarded.
Relevant Paper(s):
| Study Title | Patient Group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
|---|---|---|---|---|---|
| Treatment of Faecal Impaction with Polyethelene Glycol Plus Electrolytes (PGE + E) Followed by a Double-blind Comparison of PEG + E Versus Lactulose as Maintenance Therapy Candy DCA, et al 2006 UK | 63 children aged between 2 and eleven diagnosed with faecal impaction. The trial had two phases the initial phase tested the efficacy and safety of PEG and E, the second tested the efficacy of PEG and E compared to Lactulose. In the second phase 28 were randomised to PEG and E and 30 to Lactulose |
Randomised Control Trial | The safety and efficacy of Polyethylene Glycol is tested by oral administration for up to seven days to all 63 children. | 58 (92%) of children achieved successful disimpaction. The median time for disimpaction was 6 days | The trial doesn't compare the cathartics for their efficacy at disimpaction. |
| Daily assessments on number of successful defaecations | The successful number of defaecations per week was higher for PEG and E (9.4) compared to (5.9) for Lactulose | ||||
| Daily assessments on amount of medicine sachets taken | The mean was 0.91 for children taking PEG and E, the mean for Lactulose was 2.41 | ||||
| Daily assessments on use of senna as rescue treatment | After twelve weeks of treatment none of the children on PEG and E took senna, compared to 8 who were on Lactulose | ||||
| If the children reimpacted after treatment | None of the children on PEG and E reimpacted compared to seven who were on Lactulose | ||||
| Polyethylene glycol 4000 vs. lactulose for the treatment of neurogenic constipation in myelomeningocele children: a randomized-controlled clinical trial Rendeli C, et al, 2006 Italy | 64 children with chronic neurogenic constipation completed the trial. Children with chronic neurogenic constipation randomised to either receive Lactulose or PEG 3350 for a period of six months |
Randomised Control Trial | Bowel frequency per week at one month | Mean- 5.2 compared to 2.1 previously for PEG 3350, 3.1 compared to 2.2 previously for Lactulose. Constipation resolved in 46% of patients taking PEG 3350, compared to 26% taking Lactulose | Children had chronic neurogenic constipation. The trial was not blinded |
| Bowel frequency per week at six months | 5.1 in PEG 3350 group compared to 2.9 in the Lactulose group. Success rate of treatment 46% in PEG 3350 group compared to 22% in the Lactulose group | ||||
| Side effects | No significant side effects found in either group | ||||
| Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children Dupont C, et al 2005 France | 64 children with chronic neurogenic constipation completed the trial. Children with chronic neurogenic constipation randomised to either receive Lactulose or PEG 3350 for a period of six months 96 children aged between 6 months and 3 years 96 ambulatory constipated children treated for a period of 3 months with either lactulose or PEG in a double blind, double dummy RCT. |
Randomised Control Trial | Mean number of stools per week. | In babies- PEG- 8.5, Lactulose-11, In toddlers, PEG-8, Lactulose-6, Results not significant | The trial wasn't strictly geared towards comparing efficacy of the different drugs and was more interested in finding out the tolerability of PEG. |
| Number of children experiencing hard stools | At day 42, PEG-9%, Lactulose-34%, Day 84 PEG-6%, Lactulose-28% | ||||
| Presence of faecal impaction | PEG- 2%, Lactulose-13% | ||||
| Tolerance or each Cathartic | Both treatments were well tolerated | ||||
| PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial Voskuijl W, et al, 2004 Netherlands | 100 children aged between 6 months and 15 years with paediatric constipation. To compare the clinical efficacy and safety of PEG 3350 with lactulose |
Randomised Control Trial | Frequency of stools at week eight | No significant difference between treatments | |
| Frequency of encopresis at week eight | No significant difference between treatments | ||||
| Overall treatment success at week eight | PEG-56% successfully treated, Lactulose- 29% | ||||
| Adverse gastrointestinal events | Fewer side effects reported with PEG than Lactulose | ||||
| After children on Lactulose switched to PEG | The success rate increased from 29% to 46% after 26 weeks of follow up | ||||
| Comparison of Polyethylene Glycol 3350 David A. Gremse, et al 2002 USA | 37 children aged between 2 and 16 years | Randomised Control Trial | Number of patients medicine was effective in | PEG 3350-84%, Lactulose-46% | Small patient group There was no long term follow up of the patients, long term effects of the treatment was not recorded |
| Bowel frequency during 14 day treatment period | PEG 3350- 14.8, Lactulose-13.5 | ||||
| Colonic transit time | Significantly shorter for PEG 3350 | ||||
| Stool consistency | Similar for both medications | ||||
| Ease of stool passage | Similar for both medications |
Author Commentary:
The commonest treatment options for constipation in children are Lactulose and PEG. The studies quite clearly show an advantage in the use of PEG over Lactulose. PEG has been shown to have fewer or similar amount of side effects as Lactulose. PEG has been shown to be a good choice for disimpaction and maintenance therapy after successful disimpaction. The trials show that patients on PEG have an increased bowel frequency than Lactulose. The trials also show that fewer patients reimpact whilst on PEG as maintenance therapy. The trials also show that PEG is a better treatment option even if the child doesn't have faecal impaction. Although the patient groups in the trials were a bit small a clear clinical advantage in the use of PEG over Lactulose has been found.
Bottom Line:
In children who present with constipation with or without faecal impaction, PEG would be a better treatment than Lactulose.
References:
- Candy DCA, et al. Treatment of Faecal Impaction with Polyethelene Glycol Plus Electrolytes (PGE + E) Followed by a Double-blind Comparison of PEG + E Versus Lactulose as Maintenance Therapy
- Rendeli C, et al,. Polyethylene glycol 4000 vs. lactulose for the treatment of neurogenic constipation in myelomeningocele children: a randomized-controlled clinical trial
- Dupont C, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children
- Voskuijl W, et al,. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial
- David A. Gremse, et al. Comparison of Polyethylene Glycol 3350